Q2 2012 · —
Revenue$210.17M$210.17M +8.7% vs Q2 2011+7.1% vs Q1 2012
Net Income$8.51M$8.51M +1,118.0% vs Q2 2011+27.2% vs Q1 2012
EPS Diluted$0.30$0.30 +1,400.0% vs Q2 2011+30.4% vs Q1 2012
Gross Profit$131,896,000+9.5%
Operating Income$18,021,000+125.3%
Operating Cash Flowderived$2,276,000−90.7%
Free Cash Flowderived-$11,954,000N/M
Margins · derived
Gross margin62.8%+0.4 pt vs Q2 2011
Operating margin8.6%+4.4 pt vs Q2 2011
Net margin4.1%+3.7 pt vs Q2 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2012 | Q2 2011 | Q2 2010 | Q2 2009 |
|---|---|---|---|---|
| Revenue | $210.17M | $193.33M | $178.60M | $165.73M |
| Net Income | $8.51M | $699.00K | $15.16M | $11.23M |
| EPS Diluted | $0.30 | $0.02 | $0.50 | $0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR